The expression of estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2) together with clinicopathological data such as Ki-67-expression, tumor size, tumor grade, and lymph node stage (N-stage), are conventionally used for patient management. This evidence concerns the gene ESR1 and neoplasm.